Navigation Links
Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Onyx
Date:9/18/2013

n addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products.  Amgen believes that some of its newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Amgen's products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with its products.  In addition, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors and there can be no guarantee of Amgen's ability to obtain or maintain patent protection for its products or product candidates.  Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of its existing products.  Amgen's stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates.  Further, the discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on Amgen's business and results of operations.

Additional Information
This communication is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of Onyx Pharmaceuticals, Inc. or any other securities.  Arena Acquisition Company and Amgen Inc. have filed a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, with the United States Securities and Exchange Commission (the "SEC") and a Solicitation/Recommendation Statement on Schedule 14D-9 has bee
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
2. Amgen To Participate At Citis 8th Annual Biotech Conference
3. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
4. Amgen to Highlight New Data at Upcoming ESC Congress 2013
5. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
6. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
7. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
8. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
9. Amgen Announces Webcast of 2013 Second Quarter Financial Results
10. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
11. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Medina Medical announced today ... member of the Board of Directors on August 18, ... development and commercialization experience, including over a decade of ... served as a Partner of the medical device incubator ... of two Foundry start-ups. Mr. Engelson previously served as ...
(Date:8/29/2014)... Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September ... and Chief Executive Officer, will provide an update on ... (9:55 a.m., Pacific Daylight Time).   A ...
(Date:8/29/2014)...  BC Technical, the nation,s leading non-OEM provider of ... leader in sales, service and installation of GE MRI ... to continue to expand their resources and inventory while ... "We are committed to driving higher ... president and CEO of BC Technical. "We set out ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2BC Technical Acquires Polaris Medical Imaging 2
... , HOUSTON and DALLAS , Feb. ... the company,s management, medical staff, and employees, are making multiple monetary and ... in Haiti . , In response to the magnitude 7.0 quake, ... and over 195,000 awaiting medical attention, First Choice owner Jack Novak ...
... , VIENNA, Va. , Feb. 3 ... Geert Kersten , Chief Executive Officer, will be presenting at the ... Organization (BIO), the conference will take place February 8-9 ... presentation will be on Tuesday, February 9th , at ...
Cached Medicine Technology:First Choice ER to Donate Over $15,000 in Medical Supplies to Haitian Earthquake Victims 2CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference 2
(Date:8/29/2014)... review of clinical trials based on administering antidepressants ... concluded that more trials are needed to determine ... pain on a regular basis., Dr. Ian Gilron, ... in the Department of Anesthesiology, and his team ... whether the use of antidepressants for pain relief ...
(Date:8/29/2014)... by the Mental Health Commission of Canada identifies ... education that police personnel receive. , "People with ... police community, and today,s report builds on the ... with mental illnesses," says Queen,s adjunct professor Dorothy ... the area of police psychology. "This is a ...
(Date:8/29/2014)... US Preventive Services Task Force recommendations for screening and ... may be ameliorated through technological approaches according to a ... published online August 21, 2014 in the Journal ... David Levine, MD, MA, a third year resident in ... colleagues found that compared to usual care, technology-assisted interventions ...
(Date:8/29/2014)... New York, New York (PRWEB) August 29, 2014 ... died from cardiac arrest following a series of dialysis ... that alleges her death was the result of ... Liebhard LLP reports. The family’s lawsuit, which was file ... 2014, claims that the use of the products resulted ...
(Date:8/29/2014)... 29, 2014 A team of experts ... is on its way to the 2014 National Safety ... Convention Center to exhibit and demonstrate a suite of ... industrial environments. Etymotic’s safety earphones and high-definition earplugs are ... at the show. , The company’s HD5 high-definition, ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:Report advocates improved police training 2Health News:Options for weight loss your primary care doctor might not know about 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 4Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2
... Operating Cash Flow of $173 Million, and Generates $98 ... to Reflect Year-to-Date Sales Results, Maintains Bottom-Line GuidanceAUSTIN, Texas, ... WFMI ) today reported results for the 12-week ... the quarter were $1.9 billion, in line with the ...
... clinical trial led by Dr. Katherine Borden, at the ... the Universit de Montral, has shown that a common ... of cancer patients. Published in the journal Blood ... the activities of the eIF4E gene in patients. This ...
... American Pathologists today joined a lawsuit against the U.S. Patent and ... for the genes known as BRCA1 and BRCA2, which are indicators ... ... Washington, D.C. (Vocus) May 13, 2009 -- The College of ...
... the findings of a landmark drug comparison study published in ... other medications for high blood pressure. A scientific team including ... Houston reports the findings in the May 11 issue of ... in three adults in the United States has high blood ...
... be the newest "Biggest Loser" but she is a real ... is about simple, everyday choices that can help you be ... the glass and is one of the simplest things you ... and athletes to don a ,stache for the National Milk ...
... combination medication approved with the extended-release form of ... Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, ... announced that the U.S. Food and Drug Administration ... medication ACTO plus met(R) (pioglitazone HCl and ...
Cached Medicine News:Health News:Whole Foods Market Reports Second Quarter 2009 Results 2Health News:Whole Foods Market Reports Second Quarter 2009 Results 3Health News:Whole Foods Market Reports Second Quarter 2009 Results 4Health News:Whole Foods Market Reports Second Quarter 2009 Results 5Health News:Whole Foods Market Reports Second Quarter 2009 Results 6Health News:Whole Foods Market Reports Second Quarter 2009 Results 7Health News:Whole Foods Market Reports Second Quarter 2009 Results 8Health News:Whole Foods Market Reports Second Quarter 2009 Results 9Health News:Whole Foods Market Reports Second Quarter 2009 Results 10Health News:Whole Foods Market Reports Second Quarter 2009 Results 11Health News:Whole Foods Market Reports Second Quarter 2009 Results 12Health News:Whole Foods Market Reports Second Quarter 2009 Results 13Health News:Whole Foods Market Reports Second Quarter 2009 Results 14Health News:Whole Foods Market Reports Second Quarter 2009 Results 15Health News:Whole Foods Market Reports Second Quarter 2009 Results 16Health News:Whole Foods Market Reports Second Quarter 2009 Results 17Health News:Whole Foods Market Reports Second Quarter 2009 Results 18Health News:Whole Foods Market Reports Second Quarter 2009 Results 19Health News:Whole Foods Market Reports Second Quarter 2009 Results 20Health News:Whole Foods Market Reports Second Quarter 2009 Results 21Health News:Novel therapy may prove effective in treatment of 30 percent of cancers 2Health News:CAP Joins Landmark Lawsuit Challenging Legality of Myriad Genetics Gene Patents 2Health News:New research confirms milestone study on blood pressure meds 2Health News:New research confirms milestone study on blood pressure meds 3Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 2Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 3Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 4
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Micro emulsifying needles, 18G....
Micro 2000, micro scissors micro 2000 supercut....
Yasargil clip applying forceps Mini. Stainless steel jaw....
Medicine Products: